Stephen MBA - Innoviva Chief Officer
| INVA Stock | USD 17.55 0.10 0.57% |
Executive
Stephen MBA is Chief Officer of Innoviva
| Age | 58 |
| Address | 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010 |
| Phone | 650 238 9600 |
| Web | https://www.inva.com |
Innoviva Management Efficiency
The company has return on total asset (ROA) of 0.0937 % which means that it generated a profit of $0.0937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0997 %, meaning that it created $0.0997 on every $100 dollars invested by stockholders. Innoviva's management efficiency ratios could be used to measure how well Innoviva manages its routine affairs as well as how well it operates its assets and liabilities. At present, Innoviva's Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Equity is forecasted to decline to 0.26. At present, Innoviva's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 944.3 M, whereas Other Assets are forecasted to decline to about 131.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Edna Maneval | Oric Pharmaceuticals | 64 | |
| Mustapha Parekh | Design Therapeutics | N/A | |
| JD Esq | Erasca Inc | 52 | |
| Erica Osbourne | ESSA Pharma | N/A | |
| Neil Thapar | ESSA Pharma | N/A | |
| Loleta Harris | ESSA Pharma | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
| Kevin Shaw | NextCure | 49 | |
| Josiah Craver | Sensei Biotherapeutics | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Udayan MD | NextCure | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Chandtip Chandhasin | ESSA Pharma | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
Management Performance
| Return On Equity | 0.0997 | ||||
| Return On Asset | 0.0937 |
Innoviva Leadership Team
Elected by the shareholders, the Innoviva's board of directors comprises two types of representatives: Innoviva inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innoviva. The board's role is to monitor Innoviva's management team and ensure that shareholders' interests are well served. Innoviva's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innoviva's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pavel CFA, Chief Officer | ||
| Patricia Drake, I Therapeutics | ||
| Marianne CPA, Chief Secretary | ||
| Stephen MBA, Chief Officer |
Innoviva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innoviva a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0997 | ||||
| Return On Asset | 0.0937 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.48 % | ||||
| Current Valuation | 1.29 B | ||||
| Shares Outstanding | 62.6 M | ||||
| Shares Owned By Insiders | 1.06 % | ||||
| Shares Owned By Institutions | 98.94 % | ||||
| Number Of Shares Shorted | 10.75 M | ||||
| Price To Earning | 5.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innoviva offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innoviva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innoviva Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innoviva Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Earnings Share 0.8 | Revenue Per Share 5.6 | Quarterly Revenue Growth 0.331 | Return On Assets 0.0937 |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.